Aquestive Therapeutics, Inc. AQST
At closeNov 3, 2026, 7:33 PM EST
After hours · Nov 3, 7:33 PM ET
- YTD
- -39.94%
- 1 year
- -40.22%
- Market cap
- 486.99M
- Revenue (ttm)
- 58.90M
- Profit margin
- -59.75%
- EPS (ttm)
- -0.68
- Shares out
- 91.18M
- Forward P/E
- -5.87
- YTD return
- -39.94%
- 1-year return
- -40.22%
- Volume
- 2.04M
- Avg volume
- 2.74M
- Open
- 3.78
- Previous close
- 3.77
- Day's range
- 3.78 – 3.94
- 52-week range
- 2.93 – 6.85
- Beta
- 2.82
- Analysts
- Strong Buy
- Price target
- 10.83 (+179.2%)
- Earnings date
- Aug 6, 2024
6M -0.34 (-8.06%)
Key statistics
- Enterprise value
- 291.78M
- PEG ratio
- 0.00
- Price / sales
- 5.45
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 4.20%
- Free cash flow
- -12.32M
- Total cash
- 77.89M
- Total debt
- 36.87M
- Return on equity
- 0.00%
- Short % of float
- 13.33%
- 50-day average
- 4.68
- 200-day average
- 4.02
Analyst view
Consensus: strong buy
- Target (low)
- 5.50
- Target (mean)
- 10.83
- Target (high)
- 17.00
- Strong buy4
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 6, 2024
Expected Aug 6, 2024. Consensus EPS estimate -0.1325.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2024 | Sep 1, 2024 | -0.12 | -0.13 | -0.01 | -8.33% |
| Aug 6, 2024 | Jun 1, 2024 | -0.11 | -0.03 | +0.08 | +72.73% |
| Aug 6, 2024 | Jun 1, 2024 | -0.11 | — | — | — |
| May 7, 2024 | Mar 1, 2024 | -0.09 | -0.17 | -0.08 | -88.89% |
| May 7, 2024 | Mar 1, 2024 | -0.09 | — | — | — |
| Mar 5, 2024 | Dec 1, 2023 | -0.08 | -0.12 | -0.04 | -50.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 20, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Dec 17, 2024 | Cantor Fitzgerald | init | — | Overweight |
| Nov 11, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 6, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 25, 2024 | Leerink Partners | main | Outperform | Outperform |
| Oct 25, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- aquestive.com
News
Aquestive Therapeutics (AQST) Reports Q3 Loss, Misses Revenue Estimates 
Aquestive Therapeutics Affirms FY2026 Sales Guidance of $46.000M-$50.000M vs $51.040M Est 
Aquestive Therapeutics Q3 EPS $(0.13) Misses $(0.11) Estimate, Sales $7.557M Miss $11.017M Estimate 
Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update 
4 Biotech Stocks Seeing Unusual Options Volume Today 
Aquestive Therapeutics to Report Third Quarter 2026 Financial Results and Recent Business Highlights on November 3 and Host Conference Call on November 4 at 8:00 a.m. ET 
Insider Selling: Aquestive Therapeutics (NASDAQ:AQST) CEO Sells $105,500.00 in Stock 
Aquestive: FDA Acceptance Of Anaphylm Resubmission Makes For Rating Upgrade 
FDA Accepts Aquestive Therapeutics’ Anaphylm NDA Resubmission; PDUFA Goal Action Date Set For March 16, 2027 
Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027
Your note
Sign in to keep a note on AQST — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARBER DANIEL | Chief Executive Officer | Stock Award(Grant) | Mar 6, 2024 | 883,302 |
| BOYD PETER E | Officer | Stock Award(Grant) | Mar 6, 2024 | 245,998 |
| BRAENDER LORI J | General Counsel | Stock Award(Grant) | Mar 6, 2024 | 323,761 |
| BRATTON DOUGLAS K | Beneficial Owner of more than 10% of a Class of Security | Stock Gift | Dec 1, 2024 | 0 |
| JUNG CASSIE | Chief Operating Officer | Sale | Nov 25, 2024 | 0 |
| KORCZYNSKI SHERRY | Officer | Stock Award(Grant) | Jun 6, 2024 | 25,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Bratton Capital Management, LP | 10.76% | 9,810,958 | 34.53M | Sep 29, 2024 |
| Blackrock Inc. | 6.39% | 5,823,077 | 20.50M | Sep 29, 2024 |
| VR Adviser, LLC | 6.09% | 5,555,555 | 19.56M | Sep 29, 2024 |
| Vanguard Group Inc | 4.68% | 4,263,796 | 15.01M | Sep 29, 2024 |
| Franklin Resources, Inc. | 3.03% | 2,766,542 | 9.74M | Sep 29, 2024 |
| MPM BioImpact Capital LLC | 1.97% | 1,796,750 | 6.32M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.64% | 2,404,170 | 8.46M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.11% | 1,920,925 | 6.76M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.23% | 1,121,385 | 3.95M | Sep 29, 2024 |
| Franklin Strategic Series-Franklin Biotechnology Discove | 1.09% | 993,800 | 3.50M | Jul 30, 2024 |
| Fidelity Small Cap Index Fund | 0.83% | 760,525 | 2.68M | Aug 30, 2024 |
| Invesco ETF Tr II-Invesco Dorsey Wright SmallCap Momentum ETF | 0.82% | 750,545 | 2.64M | Oct 30, 2024 |